Key result
Recent developments in norovirus-specific small-molecule therapeutics have primarily focused on inhibitors of norovirus 3C-like protease and RNA dependent RNA polymerase at the early discovery stage.
This perspective summarizes early-stage discovery efforts for norovirus therapeutics, highlighting viral and host-related targets.
Norovirus antivirals remain preclinical; leaves open clinical translation of 3C-like protease and polymerase inhibitors.
Noroviruses are members of the family Caliciviridae. Norovirus infections are a global health burden that impacts >20 million individuals annually in the U.S. alone. Noroviruses are associated with high morbidity among vulnerable populations, particularly immunocompromised patients. This perspective highlights recent developments related to the discovery and development of norovirus-specific small-molecule therapeutics as well as recent advances in our understanding of norovirus biology and pathogenesis. Most of the work in this area is at the early discovery stage and has been primarily focused on inhibitors of norovirus 3C-like protease and RNA dependent RNA polymerase. However, recent discoveries emanating from basic studies in norovirus research have resulted in the identification of new host-related drug targets that can be exploited. A repurposed compound has been advanced to human clinical studies.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2015) conducted a review in Norovirus infections. Norovirus-specific small-molecule therapeutics was evaluated. Recent developments in norovirus-specific small-molecule therapeutics have primarily focused on inhibitors of norovirus 3C-like protease and RNA dependent RNA polymerase at the early discovery stage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: